Hundreds of Thousands of Chinese Vaccinated with ‘Experimental’ Neocon Vaccine, West Warns

According to the Beijing News, China Biotech, a subsidiary of the state-owned China National Pharmaceutical Corporation (CNPC), has completed hundreds of thousands of experimental doses of the new canopy vaccine.

China had previously initiated the emergency use of the Neocrown vaccine, and “China Bio” accounted for two of the three approved vaccines. Reports indicate that none of the vaccine recipients have had any significant adverse reactions or infections so far.

However, the two vaccines from China Bio are still in Phase III trials. According to the Wall Street Journal, countries generally approve widespread vaccination of the public only after trials are completed. So far, the U.S., the U.K., and other countries have not approved any New Crown vaccine for public use.